Wilex, Nestle deal

Wilex exercised an option under a 2011 deal and will receive a $17.5 million payment from Nestle's Prometheus Laboratories Inc. unit in lieu of receiving European rights to commercialize an undisclosed product. Prometheus received U.S. commercialization rights to cancer candidate Rencarex girentuximab under the deal. As part of the option exercise, Wilex is also eligible for a $2.5 million milestone payment upon submission of a regulatory application for the chimeric mAb against carbonic anhydrase IX (CAIX). ...